ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...

For those and other reasons, targeted oral therapies like Bruton tyrosine kinase inhibitors (BTKis) and the BCL-2 inhibitor ...

In rodents, Amphista linked its BRD9 degrader AMX-883 to a significant improvement in survival and reduction in disease burden compared to Venclexta. Combining AMX-883 with Venclexta and azacitidine ...

Azacitidine plus venetoclax significantly improved multiple outcomes for certain patients with acute myeloid leukemia ...

In this video, Shazia K. Nakhoda, MD, discusses “exciting” data from the CLL-17 trial that showed fixed-duration therapy produces similar results inpreviously untreated chronic lymphocytic leukemia.Re ...

Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction ...

In the world of oncology drug development, the standard playbook is simple: race to earlier lines of treatment, where patient ...

RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series ...

ORLANDO -- In a phase III trial with potential practice-changing implications, the non-covalent Bruton's tyrosine kinase (BTK ...

ORLANDO -- Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit ...